|Title||Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease.|
|Publication Type||Journal Article|
|Year of Publication||2019|
|Authors||Eruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M|
|Journal||Alzheimers Dement (Amst)|
|Date Published||2019 Dec|
Introduction: Lipocalin-2 is an acute-phase protein with pleotropic functions that has been implicated in several diseases including Alzheimer's disease (AD). However, it is unknown if circulating lipocalin-2 levels are altered in the preclinical stage of AD, where AD pathology has accumulated but cognition remains relatively intact.
Methods: In this cross-sectional study, we used an immunoassay to measure plasma lipocalin-2 levels in cognitively normal (Clinical Dementia Rating 0) elderly individuals. 38 of 156 subjects were classified as preclinical AD by cerebrospinal fluid criteria.
Results: Plasma lipocalin-2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid-beta levels but not cerebrospinal fluid tau or phosphorylated-tau levels. Exploratory analyses revealed that plasma lipocalin-2 was associated with executive function but not episodic memory.
Discussion: Collectively, these results raise the possibility that circulating lipocalin-2 is involved early in AD pathogenesis and may represent an early blood biomarker of amyloid-beta pathology.
|Alternate Journal||Alzheimers Dement (Amst)|
|PubMed Central ID||PMC6733778|
|Grant List||R01 NS037853 / NS / NINDS NIH HHS / United States |
K23 NS082367 / NS / NINDS NIH HHS / United States
K08 AG051179 / AG / NIA NIH HHS / United States
P01 AG003991 / AG / NIA NIH HHS / United States
P50 AG005681 / AG / NIA NIH HHS / United States
UL1 TR002384 / TR / NCATS NIH HHS / United States
P01 AG026276 / AG / NIA NIH HHS / United States